If you have been reading about peptide hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
agencies like the DEA, underscored the necessity of international cooperation, intelligence-sharing, and advanced surveillance technologies, while also exposing the limitations of militarized approaches in addressing the socio-economic drivers of the drug trade. Guzmán's high-profile status and the Sinaloa Cartel's global reach made his capture a symbolic victory, yet it also revealed the resilience of drug trafficking networks, as the cartel continued operations unabated, reflecting the broader, ongoing struggle to dismantle such organizations in the global anti-drug campaign. The Mérida Initiative, launched in 2008, was a security cooperation program between the US and Mexico, aimed at combating drug trafficking and transnational crime. From 2008 to 2021, the US provided $3.5 billion in funding. The initial focus was anti-drug and rule-of-law measures, later broadened to include US-Mexico border activities. Components included military and law enforcement training and equipment, and technical advice and training to strengthen the national justice systems. In 2021, it was replaced by the Bicentennial Framework for Security, Public Health, and Safe Communities. In 2013, a Pew Research Center poll found that 85% of Mexican citizens supported using the Mexican army against drug cartels, 74% supported US training assistance for their police and military, 55% supported the US supplying of weapons and financial aid, and 59% were against deploying US troops on Mexican soil.
== Biomarker == Fragments derived from the ANP precursor, including the signal peptide, NT-ProANP (N-terminal pro-ANP) and ANP, have been detected in human blood. ANP (28 residues long) is the active hormone while NT-proANP (98 residues) is the remaining part of proANP after cleavage by corin. ANP and associated peptides are used as biomarkers for cardiovascular diseases such as stroke, coronary artery disease, myocardial infarction and heart failure. A part of NT-proANP called mid-regional pro-atrial natriuretic peptide (MR-proANP) is a highly sensitive biomarker in heart failure. MR-proANP levels below 120 pmol/L can be used to effectively rule out acute heart failure. MR-proANP is measured using antibodies that bind to two consecutive parts of NT-proANP, residue number 53–72 and 73–90. In contrast, traditional NT-proANP measurement use antibodies that bind to the N-terminal of NT-proANP. In either case, antibodies are only able to determine the amount of peptides matching their epitope fragments. They largely cannot differentiate between a cleaved part (NT-proANP, ANP) and the uncleaved precursor (proANP). Large amounts of ANP secretion has been noted to cause electrolyte disturbances (hyponatremia) and polyuria. These indications can be a marker of a large atrial myxoma.
=== Controversies === In July 2019, the British company Reckitt Benckiser Group (RB Group) and its current/former affiliated entities (notably Indivior, which split from RB Group in 2014) settled with the US Department of Justice (DOJ) regarding the sale and marketing of brand name Suboxone (buprenorphine/naloxone). The non-prosecution agreement involves RB Group paying up to $1.4 billion, the largest settlement payment in U.S. history involving an opioid-class medication. This record was surpassed in October 2020, when Purdue Pharma reached an $8 billion settlement for claims related to injuries and deaths caused by the opioid epidemic, which includes criminal fines, forfeiture, and civil damages. The 2019 case alleged anti-competitive behavior by RB Group and Indivior surrounding the expiration of their regulatory exclusivity for Suboxone sublingual tablets. The DOJ alleged that RB Group and Indivior employed a product hopping scheme (when a firm ceases production of a product upon expiration of regulatory exclusivity in favor of another product that still has regulatory exclusivity in order to prevent generic manufacturer competition) by misrepresenting that the Suboxone sublingual film formulation was safer than the sublingual tablet formulation because "children are less likely to be accidentally exposed to the film product". There was no scientific evidence for that claim.
The racemic form has mild amphetamine-like psychostimulant effects that are diminished compared to those of amphetamine but are still present. The levorotatory enantiomer has further reduced stimulant effects, and further work, published in 1967, determined that the levorotatory enantiomer was a more potent MAOI than the dextrorotatory enantiomer. As a result, subsequent work was done with the single enantiomer L-deprenyl. In 1968, it was discovered by J. P. Johnston that monoamine oxidase exists in multiple forms. In 1971, Knoll showed that selegiline highly selectively inhibits the B-isoform of monoamine oxidase (MAO-B) and proposed that it is unlikely to cause the infamous "cheese effect" (hypertensive crisis resulting from consuming foods containing tyramine) that occurs with non-selective MAOIs. The lack of potentiation of tyramine effect by deprenyl had previously been reported in 1966 and 1968 studies, but could not be mechanistically explained until after the existence of multiple forms of MAO was discovered. Selegiline was the first selective MAO-B inhibitor to be discovered and hence is described as prototypical of these agents. Deprenyl and selegiline were initially studied as antidepressants for treatment of depression. Deprenyl was first found to be effective for depression from 1965 to 1967, while selegiline was first found to be effective for depression in 1971 and this was further corroborated in 1980.
SPECULOOS-3 b, an exoplanet nearly identical in size to Earth, is discovered orbiting an ultracool dwarf star as small as Jupiter and located 55 light-years from Earth. Solar energy is combined with synthetic quartz to generate temperatures of more than 1,000°C. This proof-of-concept method shows the potential of clean energy to replace fossil fuels in heavy manufacturing, according to a research team at ETH Zurich. 16 May – A multimodal algorithm for improved sarcasm detection is revealed. Trained on a database known as MUStARD, it can examine multiple aspects of audio recordings and has 75% accuracy. 17 May – The world's smallest quantum light detector on a silicon chip is demonstrated, 50 times smaller than their previous version. 20 May – The first measurements of an exoplanet's core mass are obtained by the James Webb Space Telescope. This reveals a surprisingly low amount of methane and a super-sized core within the super-Neptune WASP-107b. 23 May New images from the Euclid space telescope are published, including a view of the Messier 78 star nursery. Astronomers using TESS report the discovery of Gliese 12 b, a Venus-sized exoplanet located 40 light-years away, with an equilibrium temperature of 315 K (42 °C; 107 °F). This makes it the nearest, transiting, temperate, Earth-sized world located to date. A team shows that iron instead of cobalt and nickel can be used as a cathode material in lithium-ion batteries, improving both safety and sustainability.
Sources: en.wikipedia.org
== Bibliography == NMR in Biological Research: Peptides and Proteins, American Elsevier Pub. Co, 1976 NMR of proteins and nucleic acids, Wiley, 1986 NMR In Structural Biology: A Collection Of Papers By Kurt Wuthrich, World Scientific Publishing Co Pte Ltd, 1995
Simon and Schuster. ISBN 978-1-4262-2005-0. Archived from the original on January 8, 2023. Retrieved January 8, 2023. Gainor, Chris (2001). Arrows to the Moon: Avro's Engineers and the Space Race. Burlington, Ontario: Apogee Books. ISBN 1-896522-83-1. Archived from the original on July 23, 2008. Retrieved August 2, 2019. Gatland, Kenneth (1976). Manned Spacecraft, Second Revision. New York: Macmillan Publishing Co., Inc. ISBN 0-02-542820-9. Hall, Rex; Shayler, David J. (2001). The Rocket Men: Vostok & Voskhod, The First Soviet Manned Spaceflights. New York: Springer–Praxis Books. ISBN 1-85233-391-X. Hall, Rex; Shayler, David J. (2003). Soyuz: A Universal Spacecraft. New York: Springer–Praxis Books. ISBN 1-85233-657-9. Hardesty, Von; Eisman, Gene (2007). Epic Rivalry: The Inside Story of the Soviet and American Space Race. Foreword by Sergei Khrushchev. Washington: National Geographic Society. ISBN 978-1-4262-0119-6. Harford, James J. (1997). Korolev: How One Man Masterminded the Soviet Drive to Beat America to the Moon (1 ed.). New York: John Wiley & Sons. ISBN 0-471-14853-9. Hepplewhite, T.A. (1999). The Space Shuttle Decision: NASA's Search for a Reusable Space Vehicle. Washington, DC: NASA. Jones, Eric M. (January 1, 2010). "Apollo 11 Lunar Surface Journal". Apollo Lunar Surface Journal. Internet. Archived from the original on January 16, 2012. Retrieved August 15, 2010. Kraft, Christopher C. (2001). Flight: My Life in Mission Control. New York: Dutton. ISBN 0-525-94571-7. Murray, Charles; Cox, Catherine Bly (1990). Apollo: The Race to the Moon.
Even after the 1947 partition, the Muslims from India kept migrating to Pakistan, especially Karachi and Sindh province. Wars in neighbouring Afghanistan in the 1980s and 1990s pushed millions of Afghan refugees into Pakistan, mainly in Khyber-Pakhtunkhwa and tribal areas, with some in Karachi and Quetta. Pakistan hosts one of the world's largest refugee populations. Additionally, around 2 million Bengalis and half a million undocumented individuals, purportedly from Myanmar, reside in Pakistan. Pakistan ordered the mass expulsion of undocumented Afghans in October 2023, citing national security risks. Migration of Bengalis and Rohingya to Pakistan started in the 1980s and continued till 1998. Karachi hosts a significant number of Bengali settlements, and large Rohingya migration made it one of their largest populations outside Myanmar. Karachi's Burmese community resides in various slums across the city. According to BBC, thousands of Uyghur Muslims live in Gilgit-Baltistan, some left Xinjiang, China and the thriving trading town of Kashgar in 1949, while others are later arrivals, claiming to escape political oppression. Since 1989, thousands of Kashmiri Muslim refugees fled to Pakistan, alleging rape and forced displacement by Indian soldiers.
== Origin == The tobacco etch virus encodes its entire genome as a single massive polyprotein (350 kDa). This is cleaved into functional units by the three proteases: P1 protease (1 cleavage site), helper-component protease (1 cleavage site) and TEV protease (7 cleavage sites). The native TEV protease also contains an internal self-cleavage site. This site is slowly cleaved to inactivate the enzyme (the physiological reason for this is unknown).
Madison: University of Wisconsin Press. ISBN 978-0-299-07334-3. Montejo, Esteban (2016). Barnet, Miguel (ed.). Biography of a Runaway Slave: Fiftieth Anniversary Edition. Northwestern University Press. ISBN 978-0-8101-3342-6. Morgan, Kenneth (2007). Slavery and the British Empire: From Africa to America. Oxford University Press. ISBN 978-0-19-156627-1. Postma, Johannes (2005). The Atlantic Slave Trade. University Press of Florida. ISBN 978-0-8130-2906-1. Reséndez, Andrés (2016). The Other Slavery: The Uncovered Story of Indian Enslavement in America. Houghton Mifflin Harcourt. ISBN 978-0-547-64098-3. Rodriguez, Junius P. (2007). Encyclopedia of Slave Resistance and Rebellion. Vol. 2. Westport, Conn: Greenwood Press. ISBN 978-0-313-33273-9. Shell, Robert Carl-Heinz (1994). Children of Bondage: A Social History of the Slave Society at the Cape of Good Hope, 1652–1838. Hanover, NH: University Press of New England [for] Wesleyan University Press. ISBN 978-0-8195-5273-0. Westermann, William Linn (1955). The Slave Systems of Greek and Roman Antiquity. American Philosophical Society. ISBN 978-0-87169-040-1. {{cite book}}: ISBN / Date incompatibility (help) Williams, Eric (2021). Capitalism and Slavery, Third Edition. The University of North Carolina Press. ISBN 978-1469663678. Journal articles and reviews Bartlett, Will (May 1994). "Review: Property and Contract in Economics". Economic and Industrial Democracy. 15 (2): 296–298. doi:10.1177/0143831x94152010. S2CID 220850066. Burczak, Theodore (June 2001).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.